**TCAR Dictation Report**

This is a template for physicians to use in dictating the TCAR procedure for a specific patient.

**Date of Operation**: [MM/DD/YYYY]

**Preoperative Diagnoses**: [List preoperative diagnoses here. Examples are provided below.]

* I65.[8,9] - Occlusion and stenosis of [other, unspecified] precerebral artery(ies)
* I65.[21,22,23,29] - Occlusion and stenosis of [right, left, bilateral, unspecified] carotid artery, not resulting in cerebral infarction
* I63.[131,132,133,139] - Cerebral infarction due to embolism of [right, left, bilateral, unspecified] carotid artery
* I63.[031,032,033,039] - Cerebral infarction due to thrombus of [right, left, bilateral, unspecified] carotid artery
* I63.[231,232,233,239] - Cerebral infarction due to unspecified occlusion or stenosis of [right, left, bilateral, unspecified] carotid arteries
* G45.9 - Transient cerebral ischemic attack, unspecified

**Indications**: [Examples are provided below. Document indications required per patient’s coverage policy.]

* Degree of Stenosis: [% of stenosis] carotid artery stenosis as indicated by [CTA/duplex ultrasound].
* Symptomatic Status: Symptomatic or Asymptomatic. Symptoms usually include focal cerebral ischemia (transient ischemic attack or monocular blindness) in the previous 120 days, symptom duration less than 24 hours, or nondisabling stroke.
* High Risk for Carotid Endarterectomy: Significant comorbidities and/or anatomic risk factors include but are not limited to:
	+ Age > 80 years old
	+ Congestive heart failure (CHF) class III/IV
	+ Left ventricular ejection fraction (LVEF) < 30%
	+ Unstable angina
	+ Contralateral carotid occlusion
	+ Recent myocardial infarction (MI)
	+ Previous CEA with recurrent stenosis
	+ Prior radiation treatment to the neck

**Operation Performed**: [Left/Right common/internal] carotid artery with Transcarotid Artery Revascularization (TCAR) using the ENROUTE® Transcarotid Neuroprotection (embolic protection) and Stent Systems

**Anesthesia**: [General/Local anesthesia]

**Complications**: [Report complications, if any]

**Blood Loss**: [Characterize blood loss]

**Procedure Findings**: [Describe procedure findings; examples of findings are provided below.]

1. Moderately calcified, nearly occlusive, ulcerative plaque in proximal right internal carotid artery.
2. Excellent temporary flow reversal established by the ENROUTE® Transcarotid Neuroprotection System (embolic protection) prior to lesion engagement.
3. Placement of the ENROUTE® Transcarotid Stent to cover the length of the lesion in the [left/right common/internal] carotid artery.
4. The patient awoke from anesthesia neurologically intact.

**Description of Procedure**: [Describe procedure here; an example description follows.] The patient was brought to the operating room, where support lines were placed, and general anesthesia was secured. The right neck and left groin were prepped, and the patient was sterilely draped. A transverse 2-4 cm incision was made between the sternal and clavicular heads of the sternocleidomastoid muscle, below the omohyoid. Following longitudinal division of the carotid sheath the jugular vein was partially dissected and retracted medially. Once 3 cm of [common/internal] carotid artery [CCA/ICA] were isolated, umbilical tape was placed around the proximal 1/3 of the [CCA/ICA] under direct vision. A 5.0 polypropylene suture was pre-placed in the anterior wall of the [CCA/ICA], in a “U stitch” configuration, close to the clavicle to facilitate hemostasis upon removal of the arterial sheath at completion of the TCAR procedure.

The contralateral [left/right] common femoral vein (CFV) was accessed under ultrasound guidance, using standard Seldinger and micropuncture access technique. Permanent recorded image(s) was/were saved in the patient's medical record. The Venous Return Sheath was advanced into the CFV over the 0.035” wire provided. Blood was aspirated from the flow line followed by flushing of the Venous Sheath with heparinized saline. The Venous Sheath was secured to the patient’s skin with suture to maintain optimal position in the vessel.

Heparin was given to obtain a therapeutic activated clotting time >250 seconds prior to arterial access. A 4-French non-stiffened ENHANCE® Transcarotid Peripheral Access Kit was used, puncturing the artery with the 21G needle through the pre-placed “U” stitch while holding gentle traction on the umbilical tape to stabilize and centralize the [CCA/ICA] within the incision. Careful attention was paid to the change in [CCA/ICA] shape when using the umbilical tape to control or lift the artery. The micropuncture wire was then advanced 3-4 cm into the [CCA/ICA] and, the 21G needle was removed. The micropuncture sheath was advanced 2-3 cm into the [CCA/ICA] and the wire and dilator were removed. Pulsatile backflow indicated correct positioning. The provided 0.035" J-tipped guidewire was inserted as close as possible to the bifurcation without engaging the lesion. After micropuncture sheath removal, the Transcarotid Arterial Sheath was advanced to the 2.5cm marker and the 0.035” wire and dilator were then removed. Transcarotid Arterial Sheath position was assessed under fluoroscopy in two projections to ensure that the sheath tip was oriented coaxially in the [CCA/ICA]. Transcarotid Arterial Sheath was sutured to the patient with gentle forward tension. Blood was slowly aspirated followed by flushing with heparinized saline. No ingress of air bubbles through the passive hemostatic valve was observed. The stopcocks were closed. Traction applied to the [CCA/ICA] previously to facilitate access was gently released.

The Flow Controller was connected to the Transcarotid Arterial Sheath, prepared by passively allowing a column of arterial blood to fill the line and connected to the Venous Return Sheath. [CCA/ICA] inflow was occluded proximal to the arteriotomy with a vascular clamp to achieve active flow reversal. To confirm flow reversal, a saline bolus was delivered into the venous flow line on both “High” and “Low” flow settings of the Flow Controller. Angiograms were performed with slow injections of a small amount of contrast filling just past the lesion to minimize antegrade transmission of micro-bubbles.

Prior to lesion manipulation, heart rate (70bpm) and systolic BP (140-160mmHg) were managed upwards to optimize flow reversal and procedural neuroprotection. The lesion was crossed with an 0.014” ENROUTE® Guidewire and pre-dilation of the lesion was performed with a 5mm x 20mm rapid exchange 0.014” compatible balloon catheter to 8 atmospheres for 10 seconds. Stenting was performed with an 9mm x 40mm ENROUTE® Transcarotid Stent, sized appropriately to the right [CCA/ICA]. AP and lateral angiograms (gentle contrast injections) were performed to confirm stent placement and arterial wall stent apposition.

At TCAR case completion, antegrade flow was restored by releasing the clamp on the [CCA/ICA] then closing the NPS stopcocks to the flow lines. The Transcarotid Arterial Sheath was removed, and the pre-closure suture was tied. Heparin reversal was employed, and a drain was placed.

The Venous Return Sheath was removed, and hemostasis was achieved with brief manual compression.

The patient tolerated the procedure well and was extubated on the table. The patient was moving all four extremities to command prior to transfer to the recovery room.

**Additional Information**: [Optional: List primary CPT codes for TCAR procedure.]

* 37215 - Transcatheter placement of intravascular stent(s), cervical carotid artery, open or percutaneous, including angioplasty, when performed, and radiological supervision and interpretation; with distal embolic protection
* 76937-26 - Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent real time ultrasound visualization of vascular needle entry, with permanent recording and reporting (List separately in addition to code for primary procedure)

Silk Road Medical has compiled this information for your convenience. Silk Road Medical cannot guarantee success in obtaining coverage or payment. It is always the provider’s responsibility to determine the appropriateness of any treatment and accurately describe patient characteristics and services furnished. Providers should consult with their payers regarding appropriate documentation, medical necessity, and coding information consistent with individual payer requirements and policies. This document is in no way intended to promote the off‐label use of any medical device. AP-144.C